ASIA-PACIFIC DNA VACCINES MARKET FORECAST 2017-2025

ASIA-PACIFIC DNA VACCINES MARKET FORECAST 2017-2025

  • October 2017 •
  • 78 pages •
  • Report ID: 5129379
KEY FINDINGS
The Asia-Pacific DNA vaccine market was calculated to be worth $154 million in 2016 and is predicted to generate a revenue of $4874 million by 2025, growing at a CAGR of 45.85%.

MARKET INSIGHTS
The Asia-Pacific market is predicted to witness the highest growth over the forecast period due to factors like increasing government backing, growing interest in third generation vaccine innovations, and growing number of medical service organizations in the region. The APAC market is segmented on the basis of technology, types, and applications. The major aspects threatening the market expansion for this region include the lengthy regulatory process and the poor patent protection methodologies.

COMPETITIVE INSIGHTS
Some of the leading companies in the market include Zoetis Inc, Merck & Co, Glaxosmithkline Inc, Sanofi, Astellas Pharma Inc, Novartis Ag, Xenetic Biosciences Inc, Madison Vaccines Incorporated (MVI), Dendreon Corporation, and Eli Lilly And Company.